Princeton, NJ – November 18, 2016 - Taiho Oncology Inc. (USA) has announced plans to form Taiho Pharma Canada, Inc., a Canadian subsidiary of Taiho Pharmaceutical Co., LTD (Japan). The Canadian operations will be managed by Taiho Oncology, Taiho’s US R&D and commercial operations, based in Princeton, NJ. Current plans are to locate the Canadian headquarters in the Peel/York regions of the Greater Toronto Area.
The planned establishment of Taiho Pharma Canada, Inc. was motivated by the recent successful NDA approval and commercial launch of Taiho Oncology Inc.’s first cancer product in the US. It also represents another step towards the globalization of Taiho Oncology Inc. and providing cancer patients throughout the world with new and innovative chemotherapies for treatment of a wide range of tumor types.
About Taiho Oncology, Inc. (U.S.)
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established world class clinical development and commercial organizations that work urgently to develop and market innovative cancer treatments in the U.S. Taiho Oncology Inc. has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It’s our work; it’s our passion; it’s our legacy.
For more information about Taiho Oncology, Inc. please visit: http://www.taihooncology.com.